- Home
- PBT vs KURA Comparison
PBT vs KURA Comparison
Compare PBT & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBT | KURA |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 841.6M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PBT | KURA |
|---|---|---|
| Price | $29.00 | $8.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | 160.3K | ★ 2.2M |
| Earning Date | 03-13-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $11.70 | $5.45 |
| 52 Week High | $32.25 | $12.49 |
Technical Indicators
Market Signals| Indicator | PBT | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 43.72 |
| Support Level | $27.67 | $8.80 |
| Resistance Level | $32.25 | $9.82 |
| Average True Range (ATR) | 1.66 | 0.55 |
| MACD | -0.30 | -0.13 |
| Stochastic Oscillator | 43.96 | 13.90 |
Price Performance
Historical ComparisonAbout PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.